Argus lifted their price target on shares of Mylan (NASDAQ: MYL) from $32.00 to $35.00 in a research note issued on Monday. The firm currently has a “buy” rating on the stock.

A number of other analysts have also recently weighed in on MYL. Analysts at Guggenheim raised their price target on shares of Mylan from $26.00 to $30.00 in a research note to investors on Thursday. They now have a “neutral” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Mylan from $31.00 to $33.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Sanford C. Bernstein raised their price target on shares of Mylan from $31.00 to $33.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock.

Mylan traded up 2.09% on Monday, hitting $30.73. Mylan has a 52-week low of $20.21 and a 52-week high of $30.77. The stock’s 50-day moving average is currently $28.67. The company has a market cap of $12.502 billion and a price-to-earnings ratio of 19.80.

Mylan, Inc. develops and markets generics along with a number of proprietary drugs. The Company’s product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson’s disease, and a wound care product to treat diabetic foot ulcers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.